Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Lenalidomide maintenance therapy prolonged progression‐free survival (PFS) versus placebo in elderly patients with diffuse large B‐cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thieblemont, Catherine, Howlett, Susannah, Casasnovas, René‐Olivier, Mounier, Nicolas, Perrot, Aurore, Morschhauser, Franck, Fruchart, Christophe, Daguindau, Nicolas, van Eygen, Koen, Obéric, Lucie, Bouabdallah, Reda, Pica, Gian Matteo, Nicolas‐Virezelier, Emmanuelle, Abraham, Julie, Fitoussi, Olivier, Snauwaert, Sylvia, Eisenmann, Jean‐Claude, Lionne‐Huyghe, Pauline, Bron, Dominique, Tricot, Sabine, Deeren, Dries, Gonzalez, Hugo, Costello, Régis, Le Du, Katell, da Silva, Maria Gomes, Grosicki, Sebastian, Trotman, Judith, Catalano, John, Caballero, Dolores, Greil, Richard, Cohen, Amos M., Gaulard, Philippe, Roulin, Louise, Takeshita, Kenichi, Casadebaig, Marie‐Laure, Tilly, Hervé, Coiffier, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154674/
https://www.ncbi.nlm.nih.gov/pubmed/31702836
http://dx.doi.org/10.1111/bjh.16300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154674/
https://www.ncbi.nlm.nih.gov/pubmed/31702836
http://dx.doi.org/10.1111/bjh.16300

Ejemplares similares